

OncoPharm
John Bossaer
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Episodes
Mentioned books

Jan 19, 2018 • 18min
Landmarks in Oncology Pharmacy: MOPP
The Landmarks series continues with DeVita's original MOPP (Hodgkin's Disease) publication from 1970. Discussion points include WBC monitoring, why cyclophosphamide isn't included, and wigs.

12 snips
Jan 12, 2018 • 15min
Foundations in Oncology Pharmacy: Cisplatin
The Foundations in Oncology Pharmacy series begins with the penicillin of oncology: cisplatin. Discussion of its history, current uses, & toxicities. Perfect for those new to oncology pharmacy.

Jan 5, 2018 • 20min
Updates in Oncology Pharmacy: Adjuvant pertuzumab & nilotinib discontinuation (CML)
Review of recent FDA action re: oncology pharmacy including review of the APHINITIY trial and pertuzumab's subsequent approval in the adjuvant setting. Also, the nilotinib label change allowing for discontinuation in CML patients is discussed.

Jan 1, 2018 • 14min
Landmarks in Oncology Pharmacy: Acute Leukemia in 1958
In the 1st of the Landmarks series, we look back at a pivotal article published in Blood in 1958 on the treatment of acute leukemia.

Dec 18, 2017 • 24min
2017 Was A Good Year
2017 saw A LOT of #oncopharm approvals. Oncology pharmacist & educator John Bossaer runs through some of the most notable oncology pharmacy trends of the year, include CAR-T cell therapy

Nov 30, 2017 • 17min
Tales of Brave Iressa
Discussion of gefitinib's journey back to the market and lessons to be learned from it by oncology pharmacist & educator John Bossaer.

Nov 17, 2017 • 19min
Adjuvant TKIs?
Recent FDA updates & a brief discussion about adjuvant TKI use in solid tumors.

Nov 1, 2017 • 13min
Acalabrutinib
Oncology Pharmacy Podcast discussing the FDA-approval of acalabrutinib